Patent Foramen Ovale (PFO) Detection
A shunt is an abnormal communication between the right and left sides of the heart or between the systemic and pulmonary vessels, allowing blood to flow directly from one circulatory system to the other. A right-to-left shunt (RLS) allows deoxygenated systemic venous blood to bypass the lungs and return to the body.
NeuraSignal Platform for PFO Detection
Providing insight into the underlying causes of a stroke, enabling more informed treatment decisions.
Simple assessment of bubble showers with regions of interest automatically identified
Quickly lock onto cerebrovascular signals in less than two minutes
Record bubbles at rest and during Valsalva in 60 second segments
View and interpret exams from anywhere
The NG2 robotic system detected 3x the number of large shunts Spencer grade three, four, and five compared to transthoracic echo (TTE). In addition, transthoracic echo (TTE) missed 23 of the large shunts.
Patent Foramen Ovale (PFO)
A PFO is a hole between the left and right atria of the heart
Background & Prevalence
A PFO is the most common source of RLS and has been shown to have a higher prevalence in stroke patients. A PFO closure significantly reduces the rate of recurrent stroke.
NeuraSignal Benefit
A TCD bubble study is non-invasive and has 96% sensitivity for RLS detection.2 Understanding the underlying cause of a stroke allows physicians to make more informed decisions, ultimately leading to better patient management.
The addition of the NG2 Robotic TCD to our Stroke Prevention Clinic has been incredibly helpful in expediting the work-up of young stroke patients, and in more accurately determining the presence or significance of patent foramen ovale (PFO).
At our center, NeuraSignal’s NG2 robotically assisted TCD detected 4x more PFOs than TTE over 3 years. Stroke programs worldwide should strongly consider integrating this technology given the scale of its clinical impact.
Clinical Trial Results3
NG2 Intelligent Ultrasound compared to standard of care TTE for RLS detection
>3X
shunt detection rate
63.6% with NG2, 20.9% with TTE
2.7X
detection of intervenable shunts
27% with NG2, 10% with TTE
Read the full results from this groundbreaking study
Clinical Support
TCD vs TTE for PFO Detection
Katsanos, A. H., Psaltopoulou, T., Sergentanis, T. N., Frogoudaki, A., Vrettou, A. R., Ikonomidis, I., Tsivgoulis, G. (2016). Transcranial Doppler versus transthoracic echocardiography for the detection of patent foramen ovale in patients with cryptogenic cerebral ischemia: A systematic review and diagnostic test accuracy meta-analysis. Annals of Neurology. 2016 Apr;79(4):625-35.
TCD is Complementary to TTE
Tobe J, Bogiatzi C, Munoz C, Tamayo A, Spence JD. Transcranial Doppler is Complementary to Echocardiography for Detection and Risk Stratification of Patent. The Canadian journal of Cardiology, 2016 Aug;32(8):986.e9-986.e16.
NG2 vs TTE
Rubin, M., Shah, R., et al. Novel Robotic-Assisted Transcranial Doppler versus Transthoracic Echocardiography to Detect Right-to-Left Shunts. New Orleans, LA USA: International Stroke Conference – Late Breaking Abstract.
COVID-19
COVID-19 is a complex disease that can affect multiple organ systems including the brain, heart, and lungs.
Background & Prevalence
Patients with severe COVID-19 pneumonia display high levels of vascular shunting, which is correlated with low lung compliance.4
NeuraSignal Benefit
The robotic nature of NG2 enables autonomous monitoring and reduces contact between providers and patients with COVID-19.
NG2 Identifies a Different Pathophysiology of COVID-19 Pneumonia
NG2 detected microbubbles in 83% of mechanically ventilated patients, signaling vascular shunting4
Clinical Support
Pulmonary Vascular Dilatation Detected by NG2 in COVID-19 Pneumonia
Reynolds AS, Lee AG, Renz J, DeSanti, K, Liang J, Powell CA, Ventetuolo CE, Poor HD. Pulmonary Vascular Dilatation Detected by Automated Transcranial Doppler in COVID-19 Pneumonia. American Journal of Respiratory and Critical Care Medicine. August 06, 2020.
Book a Live Demo
Let's Get started
By providing noninvasive monitoring of cerebral hemodynamics, the NeuraSignal Platform can reduce the need for more invasive and costly procedures, delivering cost savings and increasing efficiency.
With real-time information, clinical teams can make more informed decisions about patient management, leading to reduced length of stay and improving patient outcomes.
With the NeuraSignal Platform, healthcare professionals can detect and manage complications more quickly, helping to prevent adverse outcomes, reduce hospital readmissions, and ultimately leading to better patient satisfaction.
References
- Ghosh AK, Jain A. Diagnosis and management of patent foramen ovale. Br J Hosp Med (Lond). 2015;76:C98–C102.
- Katsanos, A. H., Psaltopoulou, T., Sergentanis, T. N., Frogoudaki, A., Vrettou, A. R., Ikonomidis, I., … Tsivgoulis, G. (2016). Transcranial Doppler versus transthoracic echocardiography for the detection of patent foramen ovale in patients with cryptogenic cerebral ischemia: A systematic review and diagnostic test accuracy meta-analysis. Annals of Neurology, 79(4), 625–635. https://doi.org/10.1002/ana.24609
- Rubin, M., Shah, R., et al. Novel Robotic-Assisted Transcranial Doppler versus Transthoracic Echocardiography to Detect Right-to-Left Shunts. New Orleans, LA USA: International Stroke Conference – Late Breaking Abstract.
- Reynolds AS, Lee AG, Renz J, DeSanti, K, Liang J, Powell CA, Ventetuolo CE, Poor HD. Pulmonary Vascular Dilatation Detected by Automated Transcranial Doppler in COVID-19 Pneumonia. American Journal of Respiratory and Critical Care Medicine. August 2020.